Citations

Clear

623 citation(s) found for "Torres, A".

Comparison of neuropsychological side effects between contemporary radiofrequency ablative neurosurgery for psychiatric disorders and conventional neurosurgical procedures: systematic review and meta-analysis
Vilela-Filho, Osvaldo , Bannach, Matheus A., Lino-Filho, Adriano M. , Nuttin, Bart , Hariz, Marwan , Schulder, Michael , Greenberg, Benjamin David, Cosgrove, Rees, Oliveira-Souza, Ricardo de, Horn, Andreas, Sheth, Sameer A, Kubu, Cynthia S. , Salem, Sherif, Zaccariotti, Alice Jardim, Tavares, Naraiana O, Damasceno, Benito Pereira, Lozano, Andres M, Visser-Vandewalle, Veerle, Kühn, JP, Slavin, K. V., Lopes, A. Dwight, Vattimo, Edoardo FQ, Coyne, Terry, Akram, Harith, Toda, Hiroki , Halpern, Casey H. , Coenen, Volker A., Gorgulho, Alessandra, Andrade, Pablo, Wu, Hemmings , Sun, Bomin, Belmonte-De-Abreu, Paulo, Cosyns, Paul, McLaughlin, Nicole , Giordano, Prof. J., Berk, Michael, Chabardes, Stephan, Abbadi, Najia E, Salles, Antonio Afonso Ferreira De, Enslin, Nico, Sousa, Marcelo Basso de, Oliveira, José Oswaldo, Labruna, Rodrigo, Reis, Antonio Marcos dos , Jiménez-Ponce, Fiacro , Ferragut, Maria Alice, Régis, Jean, Lipsman, Nir , Rezai, Ali R. , Schuurman, Rick, Martínez-Álvarez, Roberto, Broggi, Giovanni, Huys, Daniel, Bervoets, Chris , Oliveira, P. A., Ragazzo, Paulo C., Lazaro-Munoz, Gabriel, Polosan, Mircea , Naesström, Matilda, Ribeiro, Telma MC, Lee, Kendall H, Hodaie, Mojgan , Sitnikov, Andrey, Yilmaz, Atilla, Almahariq, F., Rios, Adriana L Lopez, Gonçalves-Ferreira, António, Lozano, Andrés M. , Huys, Daniel , Enslin, Nico , Nuttin, Bart , Hariz, Marwan , Sheth, Sameer A , Damasceno, Benito Pereira , Kuhn, Jens , Slavin, Konstantin V. , Doshi, Paresh , Toda, Hiroki , Andrade, Pablo , Zrinzo, Ludvic , Chabardes, Stephan , Chang, Jin Woo , Polosan, Mircea , Hodaie, Mojgan , Almahariq, Fadi , Nico Enslin, Johannes M , Hamani, Clement , Greenberg, Benjamin D. , Oliveira‐Souza, Ricardo de , Sheth, Sameer A. , Zaccariotti, Alice Jardim , Tavares, Naraiana de Oliveira , Mayberg, Helen S. , Visser-Vandewalle, Veerle E. R. M. , Falkai, Peter , Lopes, Antonio C, Vattimo, Edoardo Filippo de Queiroz , Akram, Harith , Blomstedt, Patric C. , Quevedo, João , Belmonte-de-Abreu, Paulo Silva , Alkhani, Ahmed M. , Berk, Michael , Yatham, Lakshmi N. , Abbadi, Najia El , Salles, Antonio A. F. De, Chang, Jin Woo , Régis, Jean , Torres, Cristina V. , Taira, Takaomi , Barcia, Juan Antonio , Schuurman, Rick , Dougherty, Darin Dean , Giacobbe, Peter , Lázaro‐Muñoz, Gabriel , Naesström, Matilda , Johansson, Viktoria , Schlaepfer, Thomas Eduard , Neimat, Joseph S. , Sitnikov, A., Yilmaz, Atilla, Almahariq, Fadi, Ríos, Adriana Lucia López , Gonçalves-Ferreira, António JC.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | April 7, 2026 | Volume: 97 | Issue: 6 | Pages: 532-541

10.1136/jnnp-2025-337800 | PMID 41946555 Get It

Background Psychiatric disorders are increasingly contributing to global disability. Despite advances in conservative management, the prevalence of treatment-resistant cases remains high. Meanwhile, neurosurgery for psychiatric disorders (NPD) remains underused, largely due to strict regulations and historical concerns, particularly those related to neuropsychological side effects (NPSE). Objective To address this issue, we conducted a systematic review with meta-analysis to compare NPSE associated with radiofrequency ablative NPD to those observed in neuro-oncological, neurovascular and epilepsy surgeries. Methods PubMed, Embase and LILACS databases were searched in April 2024 for articles published in English/Spanish from 1990 to 2022, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines. Results A total of 48 articles with 2678 participants were included. The frequency of transient and permanent NPSE in the NPD group ranged from 0.94% to 11.50% and 0.94% to 2.03%, respectively, comparable to the other surgical groups (epilepsy: 0.31–11.70%; vascular: 0.52–22.90%; oncology: 0.94–17.60% for transient NPSE; epilepsy: 0.31–12%; vascular: 0.40–1.96% and oncology: 0.84–1.48% for permanent NPSE). Regarding permanent NPSE, arguably the most critical consideration, the NPD group showed better outcomes in memory, language and social cognition than the epilepsy group, but worse outcomes in executive and perceptual-motor functions. Compared with the vascular group, the NPD group had better executive function but worse complex attention. Finally, the NPD group had fewer permanent deficits than the oncology group in executive function, complex attention and perceptual-motor domains, although language performance was lower. Conclusions Contemporary NPD apparently carries a similar risk of NPSE as other conventional neurosurgical procedures, challenging misconceptions and this unjustified barrier to its broader use.
Abstract 6751: Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels
Trujillo, Steve Soto , Yang, Yan , Bartolini, Michela, Mittal, Pooja, Torres-Gonzalez, Lesly, Shah, Unnati Hemant, Lo, Jae Ho, Goretsky, Yitzhar, Zhang, W., Venook, A., Algaze, Sandra, Millstein, Joshua , Lenz, Heinz-Josef, Torres‐Gonzalez, Lesly , Bartolini, Michela, Soni, Shivani, Mittal, Pooja , Ou, Fang‐Shu , Venook, Alan P. , Algaze, Sandra , Lenz, Heinz‐Josef

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 6751-6751

10.1158/1538-7445.am2026-6751 Get It

Abstract Introduction: Fibroblast growth factor receptor 2 and 3 (FGFR2 and FGFR3) are metabolic genes overexpressed in malignant epithelia. In colorectal cancer (CRC), intimate crosstalk between FGFR2/3 and epidermal growth factor receptor (EGFR) pathways has been suggested but is not fully elucidated. As a result, this study investigated associations between FGFR2/3 expression levels and clinical outcomes in patients with metastatic CRC (mCRC) enrolled in the phase III clinical trial CALGB /SWOG 80405. Methods: Data from 433 patients with mCRC enrolled in the CALGB/SWOG 80405 trial were analyzed. Patients received either bevacizumab (bev, n = 226) or cetuximab (cet, n = 207) plus chemotherapy as first-line treatment. Tumor RNA was extracted from FFPE samples and processed through the HiSeq 2500 (Ilumina) platform. Median overall survival (OS) and progression-free survival (PFS) curves were evaluated in all treatment subgroups and stratified according to high (H), medium (M), and low (L) FGFR 2 and 3 gene expression levels. Likelihood ratio tests, hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using Cox proportional hazards multivariate models, adjusting for age, sex, ECOG performance status, tumor location, number of metastatic sites, KRAS status, consensus molecular subtypes, and treatment arm. Results: Both FGFR2 and FGFR3 expression levels were associated with outcomes in patients treated with cetuximab. FGFR2-L tumors showed significantly longer OS compared to the M (HR = 1.04; 95%CI 0.71-1.51) and H (HR = 1.56; 95%CI 1.06-2.28) expression groups (35.7 vs. 31.2 vs. 23.7 months, p = 0.017). In contrast, FGFR3-L tumors were associated with shorter OS compared to the M (HR = 0.63; 95%CI 0.44-0.92) and H (HR = 0.59; 95%CI 0.41-0.85) expression groups (24.7 vs 32.4 vs 37.1 months, p = 0.0009). Significant differences in PFS were not observed. A nominally significant interaction was found between treatment and FGFR3 expression for both PFS (p = 0.02) and OS (p = 0.0003), but no interaction with FGFR2 expression. No significant associations were detected in patients treated with bev. Neither FGFR2 nor FGFR3 suggested to be prognostic markers after multivariate adjustment analyses. Conclusions: Our findings suggest a predictive role of FGFR3 in patients with mCRC undergoing anti-EGFR treatment. Differences in survival within the cet subgroup suggest that EGFR inhibitor efficacy may be modulated by FGFR2/3 signaling activity. Interestingly, FGFR2 and FGFR3 expressions were inversely and positively correlated with improved OS. The findings suggest that FGFR2 signaling minimizes the specific effects of cetuximab, while FGFR3 signaling amplifies its therapeutic effects. Further studies should determine whether these associations are seen in other anti-EGFR inhibitors and detail the mechanistic interaction between FGFR and EGFR pathways. Citation Format: Steve Soto Trujillo, Yan Yang, Michela Bartolini, Shivani Soni, Pooja Mittal, Fang-Shu Ou, Lesly Torres-Gonzalez, Unnati Hemant Shah, Jae Ho Lo, Yitzhar Goretsky, Wu Zhang, Alan Venook, Sandra Algaze, Joshua Millstein, Heinz-Josef Lenz. Differences in survival outcomes among metastatic colorectal cancer patients across fibroblast growth factor receptor 2 and 3 expression levels [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 6751.
Abstract 1011: Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405
Yang, Yan , Bartolini, Michela, Mittal, Pooja, Torres-Gonzalez, Lesly, Shah, Unnati Hemant, Lo, Jae Ho, Trujillo, Steve Soto , Goretsky, Yitzhar, Zhang, W., Algaze, Sandra, Millstein, Joshua , Lenz, Heinz‐Josef , Torres‐Gonzalez, Lesly , Soni, Shivani, Ou, Fang‐Shu , Venook, Alan P. , Algaze, Sandra

Mayo Clinic

Cancer Research | April 3, 2026 | Volume: 86 | Issue: 7_Supplement | Pages: 1011-1011

10.1158/1538-7445.am2026-1011 Get It

Abstract Background. Mitophagy plays a crucial role in removing dysfunctional mitochondria to maintain cellular homeostasis but also has been implicated in cancer tumorigenesis. Previously, we showed that genetic variation in mitophagy pathway genes holds a predictive value in metastatic CRC (mCRC) patients (pts) treated with bevacizumab-based chemotherapy. In this study, we analyzed the correlation between tumor expression profiles of genes associated with PINK1/Parkin and BNIP3/NIX/FUNDC1 mitophagy pathways with clinical outcome in a large phase III randomized clinical trial CALGB SWOG 80405. Method. We analyzed 433 pts with mCRC treated with first-line chemotherapy in combination with the targeted agents bevacizumab (Bev, n = 226) or cetuximab (Cet, n = 207). Tumor RNA isolated from FFPE samples was sequenced using the HiSeq 2500 platform (Illumina). Median Overall survival (mOS) and median progression-free survival (mPFS) were compared across pts groups divided into high, medium, and low tertiles based on mitophagy-related gene (BNIP3, BNIP3L, PINK1, PRKN) expression levels. Likelihood ratio tests, hazard ratios (HRs), and 95% confidence intervals (CIs) were calculated using multivariable Cox proportional hazards models, adjusting for age, sex, ECOG performance status, tumor location, number of metastatic sites, KRAS status, Consensus Molecular Subtypes, and treatment arm. Results: Overall, BNIP3L demonstrated significant prognostic value for both PFS and OS after adjustment for multiple testing (false discovery rate [FDR] < 0.05). Tumors with low BNIP3L expression showed longer PFS and OS compared to those with medium or high expression levels (mPFS 14.8 vs. 10.0 vs. 9.2 months, HR 1.16, 95% CI 1.04 - 1.29p = 0.0182; mOS: 37.4 vs. 30.2 vs. 24.4 months, HR 1.22, 95% CI 1.09 - 1.38, p = 0.0036), independent of treatment. In pts treated with Cet, high PRKN expression was associated with improved PFS and OS (mPFS: 8.9 vs. 10.3 vs. 14.6 months, HR 0.79; 95% CI 0.69 - 0.91, p = 7.3e-05; mOS: 21.2 vs. 27.7 vs. 41.1 months, HR 0.87; 95% CI 0.75 - 1.01, p = 0.00084), whereas low PINK1 expression was significantly associated with longer OS (mOS: 24.9 vs. 30.9 vs. 39.2 months, HR 1.23; 95% CI 1.04 -1.46, p = 0.013). No significant associations were observed in Bev-treated patients for PRKN or PINK1. No significant results were found for BNIP3 expression analysis. Conclusion. Mitophagy is a crucial player in CRC biology due to its tumor-intrinsic (mitochondrial bioenergetics) and microenvironment (interacts with immune components) effects. Our study highlights the prognostic value of BNIP3L and predictive potential of PINK1 and PRKN, suggesting a potential combinatorial therapeutic approach using mitochondrial targeting drugs and targeted agents e.g Cet, which warrants further investigation. Support: Genentech; Clinicaltrials.gov Identifier: NCT00265850 Citation Format: Shivani Soni, Yan Yang, Michela Bartolini, Pooja Mittal, Fang-Shu Ou, Lesly Torres-Gonzalez, Unnati Hemant Shah, Jae Ho Lo, Steve Soto Trujillo, Yitzhar Goretsky, Wu Zhang, Alan P. Venook, Sandra Algaze, Joshua Millstein, Heinz-Josef Lenz. Correlation of mitophagy related genes expression and clinical outcome in metastatic colorectal cancer patients enrolled in CALGB (Alliance)/SWOG 80405 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2026; Part 1 (Regular Abstracts); 2026 Apr 17-22; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(7 Suppl):Abstract nr 1011.
An Unusual Cause of a Difficult Extubation
Gleich, Stephen J. , Mauermann, William J., Torres, Norman E.

Mayo Clinic

Respiratory Care | March 12, 2026 | Volume: 53 | Issue: 3 | Pages: 376-376

10.4187/respcare.08530376 Get It

Renal blood flow and progression to kidney failure in ADPKD
Nowak, Kristen L. , Ku, Elaine , Sarnak, Mark J, You, Zhiying, Bae, Kyongtae T, Chapman, Arlene, Perrone, Ronald D. , Torres, Vicente, Yu., A. Ershova, Chonchol, Michel, Torres, Vicente E , Nowak, Kristen L , Copeland, Timothy P. , You, Zhiying , Gitomer, Berenice Y , Abebe, Kaleab Z , Chapman, Arlene B. , Rahbari-Oskoui, Frederic F. , Chonchol, Michel

Mayo Clinic

Nephrology Dialysis Transplantation | March 11, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/ndt/gfag059 | PMID 41811969 Get It

ABSTRACT Background A decrease in renal blood flow (RBF) precedes estimated glomerular filtration rate (eGFR) decline among patients with autosomal dominant polycystic kidney disease (ADPKD) and inversely associates with disease severity and progression. However, it is unknown whether RBF independently predicts progression to kidney failure in patients with ADPKD. Methods A total of 379 participants with early-stage ADPKD (mean age 36.6 ± 8.5 years; eGFR: 92.9 ± 17.1 ml/min/1.73 m2) who participated in the Halt Progression of Polycystic Kidney Disease Study A (HALT PKD A; NCT00283686) with baseline RBF (phase contrast magnetic resonance imaging) data were included in the primary analysis. Kaplan–Meier survival analysis and multivariate Cox proportional hazard models were used to determine the association of baseline RBF as a continuous and categorical variable with kidney failure risk (during the HALT study and subsequently linked to the US Renal Data System) over a median follow-up period of 13.1 years (interquartile range 7.5–14.5) (primary outcome). All-cause mortality was also considered as a competing risk (Fine and Gray method). The associations of RBF with eGFR slope and the change in height-adjusted total kidney volume (∆htTKV) were evaluated with linear and logistic regression models. Results The kidney failure incidence rate was the highest among those with the lowest RBF tertile {1.90 [95% confidence interval (CI) 1.31–2.78] versus 0.34 [95% CI 0.14–0.83] events/100 person-years in tertile 3}. In the fully adjusted model, the lowest RBF tertile was associated with a higher risk of progression to kidney failure [hazard ratio (HR) 3.19 (95% CI 1.05–9.67] versus the highest tertile]. The association of RBF with kidney failure risk was slightly attenuated in adjusted models. All associations remained similar when considering death as a competing risk [HR 0.82 (95% CI 0.67–1.00) per 100 ml/min/1.73 m2 higher RBF]. Higher RBF was associated with a slower eGFR decline and lower odds of rapid annual ∆htTKV. Conclusions Lower baseline RBF independently associates with a greater risk of progression to kidney failure in early-stage patients with ADPKD.
Monogenic Etiologies of Kidney Cysts in the Pediatric Population
Bozkurt, Elif G. , Najeeb, Mohamad Sheikh, Yang, Hana , Kemppainen, Jennifer L., Smith, Byron H. , Gregory, Adriana , Baker, Tracy A., Thompson, W. Foster, Khalifa, Muhammed, Cruz, Conrad , Kouri, Anne M. , Tran, Cheryl L. , Sas, David J. , Cramer, Carl H. , Kline, Timothy L. , Torres, Vicente, Chebib, Fouad T., Harris, Peter, Thompson, Whitney S. , Baker, Tracy A. , Sheikh Najeeb, Mohamad, Gregory, Adriana V , Baker, Tracy A , Thompson, Whitney S , Dahl, Neera K , Kline, Timothy L , Torres, Vicente E , Chebib, Fouad T , Harris, Peter C , Hanna, Christian , Smith, Byron , Dahl, Neera K. , Chebib, Fouad T. , Harris, Peter C. , Hanna, Christian

Mayo Clinic

Clinical Journal of the American Society of Nephrology | March 6, 2026 | Volume: 21 | Issue: 6 | Pages: 984-996

10.2215/cjn.0000001027 | PMID 41790507 Get It

Key Points In a cohort of children, 79% of families with kidney cysts had a monogenic diagnosis. Resolved cases were more likely to have a family history of kidney cysts and unresolved cases more often had unilateral cysts. Broad genetic testing revealed genetic diversity and informed prognosis and clinical management in childhood kidney cysts. Background Pediatric kidney cysts may indicate an underlying genetic disorder, yet the full spectrum of causes remains incompletely defined. With advances in genetic testing enabling broader evaluation, this study assessed the diagnostic utility of comprehensive genetic testing in a broad pediatric cohort with kidney cysts and characterized the underlying etiological diversity. Methods This observational cohort study included patients younger than 18 years enrolled between January 2020 and June 2024 at a single tertiary center. Genetic testing used targeted multigene or custom curated exome/genome sequencing panels, with segregation analysis when available. Eligible participants had at least two cysts without family history, one cyst with positive family history, or enlarged echogenic kidneys on prenatal ultrasound; those with congenital anomalies of the kidney and urinary tract associated with cysts were excluded. Clinical presentation was categorized as symptomatic, incidental, prenatal, or family screening. Primary outcomes were diagnostic yield and distribution of pathogenic variants. Results Among 109 patients (median age 7.6 years, 53% female), genetic testing identified a definitive diagnosis in 81 of 100 tested patients (81%) from 72 families (79%; 14 disorders). PKD1 variants were most common (45%), while PKD2 accounted for 7%. Other causes included HNF1B or 17q12 deletions (13%), minor autosomal dominant polycystic kidney disease genes (11%; GANAB, NEK8, IFT140 ), monoallelic PKHD1 (3%), and biallelic PKHD1 (8%), while syndromic ciliopathy genes accounted for 5%. A positive family history of cystic kidney disease was more common among patients with a genetic diagnosis (54% versus 11%; P = 0.008). Patients without an identified genetic diagnosis more often had unilateral cysts (26% versus 4%; P = 0.53). Diagnosis by clinical symptoms was the most genetically diverse category. Conclusions Comprehensive genetic testing in pediatric kidney cysts achieved high diagnostic yield in a selected cohort and identified diverse causes beyond major autosomal dominant polycystic kidney disease/autosomal recessive polycystic kidney disease genes, supporting early evaluation to improve diagnostic accuracy, inform prognosis, and guide management, even in the absence of family history.
Feasibility of decentralized real-world monitoring of SARS-CoV-2 booster vaccines and COVID-19 outcomes in myeloma
Wood, William A, Kumar, Shaji K, Semmel, Emily, James, Shandra, Chung, David J., Rosenberg, Aaron S., Zonder, Jeffrey A. , Rubinstein, Samuel M., D'Souza, A, Martin, Thomas, Chari, Ajai, Vij, Ravi, Nooka, Ajay K., Anderson, Kenneth C., NEUBERG, D, Torres, Kathleen, Weiss, Brendan M. , Pederson, Levi , Geyer, Susan, Usmani, Saad Z., Wood, William A. , D’Souza, Anita , Rosenberg, Aaron S. , Wood, William A , Kumar, Shaji K , Chung, David J , Rosenberg, Aaron , D'Souza, Anita , Pederson, Levi D , Derkach, Andriy , Kumar, Shaji , Semmel, Emily A., Schroeder, Mark A. , Rubinstein, Samuel M. , Martin, Thomas, Nooka, Ajay K. , Anderson, Kenneth C., Neuberg, Donna , Richard, Shambavi , Torres, Kathleen, Derkach, Andriy , Usmani, Saad Z.

Mayo Clinic

Blood Advances | February 24, 2026 | Volume: 10 | Issue: 9 | Pages: 3094-3102

10.1182/bloodadvances.2025018963 | PMID 41734388 Get It

Abstract Patients with multiple myeloma have an elevated risk of severe complications from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; COVID-19) infection. To demonstrate proof of concept for a pandemic preparedness and response network, the American Society of Hematology Research Collaborative Multiple Myeloma Program developed a prospective, decentralized study within a site-based provider network. In the COVID-19 outcomes in myeloma and the impact of vaccines (COSMIC) study, patients provided consent, permitted electronic health record data collection, completed patient-reported outcomes at baseline, day 30, and day 180 through an electronic study portal, and were compensated for participation. Clinicians at participating sites facilitated study recruitment and shared best practices monthly to accelerate study execution. The COSMIC study rapidly consented 201 patients from 8 participating sites over 4 months (22 January 2024 through 17 May 2024). Consented participants were 30 to 93 years old, with a median age of 67; 46% were female, 69% were non-Hispanic White, 17% were non-Hispanic Black, and 8% were Hispanic/Latino. Patient-reported data completion was 97% at baseline, 81% at 1 month, and 79% at 6 months. At baseline, 55% of patients reported a history of COVID-19 infection and had received a median of 4 SARS-CoV-2 vaccines. For all patients, there were an additional 18 COVID-19 infections and 57 vaccines received during the 6-month observation period. There were no significant differences in health-related quality of life over time or by history of COVID-19 infection. COSMIC demonstrates the feasibility of an innovative evidence generation strategy to drive rapid accrual of patients to address an evolving area of need. This trial was registered at www.clinicaltrials.gov as #NCT05831787.
Abstract PS2-09-08: Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database
Chumsri, S., Deshmukh, S. Kumar, Liu, Y., Wu, S., Xiu, J., Norton, N., Gandhi, S. Shipra, Torres, E., Lustberg, M. B., Perez, E., Nassar, A., Sledge, G. W., Thompson, E., Knutson, K., Chumsri, S., Xiu, Joanne, Lustberg, Maryam , Nassar, A., Thompson, E. Aubrey , Knutson, Keith L.

Mayo Clinic

Clinical Cancer Research | February 20, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-09-08-PS2-09-08

10.1158/1557-3265.sabcs25-ps2-09-08 Get It

Abstract Background: Tertiary lymphoid structures (TLS), which are organized ectopic lymphoid aggregates resembling secondary lymphoid organs, have been associated with improved outcomes across various cancer types. However, limited data exist on the prognostic relevance of TLS in HER2+ BC pts treated with trastuzumab. In our prior work, we demonstrated that the presence of functional TLS, defined by lymphoid aggregates with elevated expression of BCL6 or IL21R, correlated with improved outcomes in the NCCTG N9831 trial. In this study, we evaluated TLS-related gene and outcomes in the real-world database. Methods: 1344 HER2+ (HR-HER2+: 560; HR+HER2+: 784) BC samples were analyzed via NGS (592-gene panel, NextSeq; WES/WTS, NovaSeq; Caris Life Sciences). Above (high) or below (low) the 50th percentile expression levels of TLS-related genes were used to calculate overall survival (OS). IL21R-high (H) and -low (L) tumors were classified by RNA expression above or below the 50th percentile. Real-world OS was derived from insurance claims and calculated from date of biopsy to last contact using Kaplan-Meier. Statistical significance was assessed using chi-square and Mann-Whitney U with multiple comparison adjustments (q < 0.05). Results: Among pts with HR-HER2+ BC, high expression of IL21R, CXCL9, CD38, and CXCL10 were associated with improved OS (Table). In contrast, among pts with HR+HER2+ BC, high expression of CXCR3, PDCD1, TBX21, CD200 and IL21R, were associated with improved OS. In both HR-HER2+ and HR+HER2+, IL21R-H groups had 1) higher infiltration of B cells (HR-HER2+: 4.4% vs 2.9%; HR+HER2+: 5.6% vs 4.2%), M1 MΦ (HR-HER2+: 3.9% vs 2.6%; HR+HER2+: 3% vs 2.1%), M2 MΦ (HR-HER2+: 4% vs 3.2%; HR+HER2+: 5.7% vs 4.4%), NK cells (HR-HER2+: 2.8% vs 2.5%; HR+HER2+: 2.7% vs 2.4%), CD8+ T cell (HR-HER2+: 0.9% vs 0%; HR+HER2+: 0.7% vs 0%), Tregs (HR-HER2+: 2.9% vs 1.4%; HR+HER2+: 2.8% vs 1.5%), all q<.05; 2) higher T cell inflamed score (HR-HER2+: 87.5 vs -95; HR+HER2+: 71 vs -86), IFNy score (HR-HER2+: -0.19 vs -0.48; HR+HER2+: -0.27 vs -0.49), all q<.05; 3) higher expression levels of MHC class I genes (HLA-A, HLA-B, HLA-C, HLA-E, FC: 1.6-2.3; all q<.05), MHC class II genes (HLA-DQA1, HLA-DOA, HLA-DPA1, HLA-DMA, FC: 2.2-3.2; all q<.05) compared to IL21R-L group. Conclusion: Consistent with our prior findings, overexpression of TLS-related genes was associated with improved outcomes in HER2+ BC in real-world data. Notably, the prognostic impact of TLS-related genes differed by hormone receptor (HR) status. Among these, IL21R emerged as the only gene significantly associated with clinical outcomes across both datasets and HR subgroups. Higher IL21R expression is associated with more B cell, M1 MΦ, CD8 T cell and NK cells. These findings underscore the potential importance of the IL21/IL21R axis in HER2+ BC and warrant further investigation to validate its role and therapeutic relevance. Citation Format: S. Chumsri, S. Deshmukh, Y. Liu, S. Wu, J. Xiu, N. Norton, S. Shipra Gandhi, E. Torres, M. Lustberg, E. Perez, A. Nassar, G. Sledge, E. Thompson, K. Knutson. Tertiary lymphoid structure (TLS)-related gene expression and outcomes in HER2-Positive (HER2+) breast cancer (BC) in the Real-World Database [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-09-08.
Risk Factors for Surgical Revision Following Ventricular Shunt Placement for Idiopathic Normal Pressure Hydrocephalus
Hamouda, Abdelrahman, Kumar, Rahul , Pennington, Zach, Naylor, Ryan M. , McQuinn, Michelle W., Potes, Maria Astudillo , Jusué-Torres, Ignacio, Loomis, Erica, Kim, Brian D. , Heller, Stephanie F. , Ballinger, Beth A. , Graff-Radford, Jonathan, Jones, D. Richard, Cutsforth-Gregory, Jeremy K., Cogswell, Petrice M., Rinaldo, Lorenzo , Meyer, Frederic B., Elder, Benjamin D., Pennington, Zach , Astudillo Potes, Maria D, Loomis, Erica A, Pennington, Zach , Kumar, Rahul , Hamouda, Abdelrahman M. , Jusué-Torres, Ignacio , Graff‐Radford, Jonathan , Jones, David T. , Cutsforth‐Gregory, Jeremy K. , Cogswell, Petrice M. , Elder, Benjamin D.

Mayo Clinic

Operative Neurosurgery | February 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/ons.0000000000001964 | PMID 41705955 Get It

BACKGROUND AND OBJECTIVES: Ventriculoperitoneal shunt (VPS) placement is a common treatment for idiopathic normal pressure hydrocephalus (iNPH), but patients may require VPS revision. This study aims to evaluate the effectiveness of a standardized VPS placement protocol by comparing indications and rates of shunt revision compared with a historical institutional cohort. METHODS: All patients treated with VPS for “suspected” iNPH at a tertiary care center between January 2000 and January 2023 were retrospectively reviewed and divided into temporally distinct historical (before 2017) and standardized (after 2017) cohorts. Cumulative incidence and timing of VPS revision were compared using competing risks analyses. RESULTS: A total of 561 patients (median age 75.0 years) were identified with 324 (57.8%) in the historical and 237 (42.2%) in the standardized cohorts. Significant variations in surgical technique and shunt hardware were noted between the cohorts. With a median follow-up of 11.4 months for historical and 12.4 months for standardized cohort, shunt revisions occurred in 19.4% and 8.4% of patients in the historical and standardized cohorts, respectively ( P < .001). Revision indications also varied significantly with lower rates of overdrainage ( P < .001), infection ( P < .001), and proximal malfunction ( P = .042) but higher rate of distal malfunction ( P = .03) in the standardized cohort. Notably, no infections were noted in the standardized cohort. CONCLUSION: Risk of shunt revision among iNPH patients may be associated with modifiable factors related to surgical technique and shunt hardware selection. Importantly, no short-term complications such as hemorrhage, infection, or catheter malposition were observed with the standardized protocol. Development and refinement of standardized shunt protocols for iNPH patients should be commonplace to facilitate tracking, identification, and modification of modifiable technical risk factors.
Abstract PS3-12-06: Immune microenvironment and survival differences among Hispanic and African American breast cancer cases by biopsy site
Deshmukh, S. Kumar, Gyabaah-Kessie, Nana, Rallos, Elexa , Al-Zubeidy, Batul , Gonzalez, E., Baugh, A. G., Carrel, Sabrina , Li, M., Zavala, Dominic, Martynova, Anastasia, Jayachandran, P., Stewart, D., Spicer, D., Wu, S. K., Xiu, Joanne , Sledge, G. W., Mahtani, R. L., Leon, A. C. Sandoval, Chumsri, S., Torres, E. T. Roussos, Hsu, Robert C. , Baugh, Aaron G. , Wu, S., Sandoval-Leon, Ana Cristina , Gandhi, Shipra , Lustberg, Maryam B. , Stern, Mariana Carla , Torres, Evanthia T. Roussos

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-12-06-PS3-12-06

10.1158/1557-3265.sabcs25-ps3-12-06 Get It

Abstract Background: Hispanic/Latinx (HL) and African American (AA) breast cancer (BC) patients (pts) have increased prevalence of high-risk features such as incidence of BC at age &lt;50 and estrogen receptor negativity. We previously showed that AA and HL had a lower fraction of neutrophils and M2 macrophages (Mɸ) despite higher percentage of PD-L1 positive cases. This study aims to further characterize differences in the tumor immune microenvironment between racial and ethnic groups, with a focus on how these differences vary by site of biopsy. Methods: We analyzed 19,459 BC samples tested by NGS (592, NextSeq; WES, NovaSeq) and WTS (NovaSeq; Caris Life Sciences). Race/ethnicity data were self-reported by pts. Immune cell proportions were estimated using WTS deconvolution (Quantiseq). Gene expression was analyzed for T-cell inflammed score (TIS), MAPK Activation Score (MPAS) and interferon-gamma (IFNy) score. Real-world overall survival (OS) data were derived from insurance claims, calculated from tissue collection or treatment initiation to last contact, and analyzed using Kaplan-Meier. Statistical significance was assessed by chi-square and Mann-Whitney U test with p-values adjusted for multiple comparisons (q&lt;0.05). Results: There were 9674 Non-Hispanic Whites (NHW) (primary BC, defined as biopsy (bx) from breast) pBC: n=3,537, 36.6%; (metastatic BC, defined as biopsy outside of the breast) mBC: n=6,137 63.4%, 1800 AA (pBC: n=750, 42%, mBC: n=1,050, 58%), and 1795 HL (pBC: n=842, 47%; mBC n=953, 53%) samples. There were 2364 TNBC (66% NHW, 19% NHB, 15% HL), 4318 HR+/HER2- (76% NHW, 11.6% NHB, 12.4% HL), and 893 HER2+ (68% NHW, 15% NHB, 17% HL). In pBC overall, AA had lower median cell fraction (%) of B cells (4.8% vs 5.3%), M2 Mɸ (3.4% vs 4.4%), but higher median cell fraction of dendritic cells (DC) (2.8% vs 2.6%) compared to NHW while HL had lower median cell fraction of M2 Mɸ (3.9% vs 4.4%) and higher median cell fraction of CD8+ T cell (0.4% vs 0.2%), all q&lt;0.05. In pBC, HL had higher IFNy score (-0.3 vs -0.34), while AA had lower MPAS (-1.2 vs -0.96), all q&lt;0.05. In lymph node bx, AA had lower median % of M2 Mɸ (3.4% vs 4.4%, q&lt;0.05). No significant differences were seen in the liver bx by race but notably there were lower median cell fractions of CD4+, CD8+, and regulatory T cells (0.0 across NHW, AA, HL) across all race/ethnicities vs. other biopsy sites. By subtype, TNBC primary bx yielded much of the significant changes with AA having lower median cell fraction of M2 Mɸ (2.49% vs 3.04%, q= 0.01) compared to NHW. In primary bx, AA (35.6 m vs 48.5 m, HR 1.4, 95% CI 1.2-1.5, p&lt;0.001) and HL (42.4 m vs 48.5 m, HR 1.2, 95% CI 1.1-1.4, p&lt;0.001) had worse median OS versus NHW. In lymph node bx, AA also had worse OS (29.2 m vs 37.2 m, HR 1.2, 95% CI 1-1.5, p=0.03) compared to NHW. In liver bx, there was worse mOS overall but no difference by race (NHW 18.65m, AA 18.79m, HL 20.6m, p =0.73). In HR+/HER2- liver bx AA had worse OS (14.2 m vs 20.9 m, HR 1.3, 95% CI 1-1.7, p=0.03) versus NHW. In HER2+ primary bx, HL had worse OS (43.2m vs 66.9m, HR 1.7, 95% CI 1.1-2.6, p=0.009). There was a trend towards worse mOS in TNBC AA patients receiving pembrolizumab (18.42m vs HL 23.69m vs NHW 35.30m; p=0.16) and HER2+ AA patients receiving trastuzumab deruxtecan (AA: 16.06m vs HL: 26.81m vs NHW: not reached; p = 0.05). Conclusions: We found race and biopsy site specific differences in the breast cancer immune microenvironment. AA pts had lower M2 Mɸ in primary and lymph node bx while NHW pts showed higher CD8+ T cell in primary tumors. Liver biopsies exhibited low T cell infiltration across all groups. AA pts had worse mOS in primary and lymph node bx compared to NHW but not in liver bx of which we saw worse mOS in all races. These results highlight the need to consider both race and bx site in treatment decisions. Citation Format: R. Hsu, S. Deshmukh, N. Gyabaah-Kessie, E. Rallos, B. Al-Zubeidy, E. Gonzalez, A. G. Baugh, S. Carrel, M. Li, D. Zavala, A. Martynova, P. Jayachandran, D. Stewart, D. Spicer, S. Wu, J. Xiu, G. W. Sledge Jr., R. L. Mahtani, A. C. Sandoval Leon, S. Gandhi, S. Chumsri, M. Lustberg, M. C. Stern, E. T. Roussos Torres. Immune microenvironment and survival differences among Hispanic and African American breast cancer cases by biopsy site [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-12-06.